Pharmacogenomics for clinical trials of COVID-19 medicines: Why is this important now?
MetadataShow full item record
CitationŞardaş, S., & Özdemir, V. (2021). Pharmacogenomics for Clinical Trials of COVID-19 Medicines: Why Is This Important Now?. Omics : a journal of integrative biology, 10.1089/omi.2021.0176. Advance online publication. https://doi.org/10.1089/omi.2021.0176
Historically, pharmacogenomics has origins in biochemical genetics in the 20th century and astute observations on unusual clinical responses to medicines. Extreme drug response phenotypes observed in the clinic have triggered molecular research on mechanisms of personto-person variations in drug safety and efficacy (Kalow, 1962; Ozdemir et al., 2009), and paved the way for the contemporary field of pharmacogenomics.